 | • レポートコード：MRC2303J0077 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、230ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートによると、2021年に249.41百万ドルであった世界の甲状腺眼症治療市場規模は、2022年に272.50百万ドルになり、2027年までにCAGR 9.43％で拡大して428.35百万ドルに達するとみられています。本書は、甲状腺眼症治療の世界市場を対象とした調査結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬剤別（コルチコステロイド、モノクローナル抗体、ビタミン）分析、投与経路別（経口薬、局所薬）分析、治療別（薬物療法、放射性ヨウ素療法、手術）分析、診断別（血液検査、画像検査、身体検査、放射性ヨウ素取り込み検査、眼窩超音波検査）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、下記の項目を掲載しています。なお、本書内の企業情報としては、Abbott Laboratories Inc.、AbbVie, Inc.、Akron Inc.、AMRI Global、Bausch & Lomb Incorporated、Bayer AG、Eyevance Pharmaceuticals LLC、Fujifilm Holdings Corporation、GlaxoSmithKline PLC、Horizon Therapeutics PLC、Immunovant, Inc.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の甲状腺眼症治療市場規模：薬剤別 - コルチコステロイドの市場規模 - モノクローナル抗体の市場規模 - ビタミンの市場規模 ・世界の甲状腺眼症治療市場規模：投与経路別 - 経口薬の市場規模 - 局所薬の市場規模 ・世界の甲状腺眼症治療市場規模：治療別 - 薬物療法の市場規模 - 放射性ヨウ素療法の市場規模 - 手術の市場規模 ・世界の甲状腺眼症治療市場規模：診断別 - 血液検査の市場規模 - 画像検査の市場規模 - 身体検査の市場規模 - 放射性ヨウ素取り込み検査の市場規模 - 眼窩超音波検査の市場規模 ・世界の甲状腺眼症治療市場規模：地域別 - 南北アメリカの甲状腺眼症治療市場規模 アメリカの甲状腺眼症治療市場規模 カナダの甲状腺眼症治療市場規模 ブラジルの甲状腺眼症治療市場規模 ... - アジア太平洋の甲状腺眼症治療市場規模 日本の甲状腺眼症治療市場規模 中国の甲状腺眼症治療市場規模 インドの甲状腺眼症治療市場規模 韓国の甲状腺眼症治療市場規模 台湾の甲状腺眼症治療市場規模 ... - ヨーロッパ/中東/アフリカの甲状腺眼症治療市場規模 イギリスの甲状腺眼症治療市場規模 ドイツの甲状腺眼症治療市場規模 フランスの甲状腺眼症治療市場規模 ロシアの甲状腺眼症治療市場規模 ... - その他地域の甲状腺眼症治療市場規模 ・競争状況 ・企業情報 |
The Global Thyroid Eye Disease Treatments Market size was estimated at USD 249.41 million in 2021 and expected to reach USD 272.50 million in 2022, and is projected to grow at a CAGR 9.43% to reach USD 428.35 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Thyroid Eye Disease Treatments to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug, the market was studied across Corticosteroid, Monoclonal Antibody, and Vitamin.
Based on Route of Administration, the market was studied across Oral and Topical.
Based on Treatment, the market was studied across Medication, Radioactive Iodine Therapy, and Surgery.
Based on Diagnosis, the market was studied across Blood Test, Imaging Test, Physical Exam, Radioactive Iodine Uptake Test, and Orbital Ultrasound.
Based on Distribution, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Thyroid Eye Disease Treatments market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Thyroid Eye Disease Treatments Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Thyroid Eye Disease Treatments Market, including Abbott Laboratories Inc., AbbVie, Inc., Akron Inc., AMRI Global, Bausch & Lomb Incorporated, Bayer AG, Eyevance Pharmaceuticals LLC, Fujifilm Holdings Corporation, GlaxoSmithKline PLC, Horizon Therapeutics PLC, Immunovant, Inc., Kala Pharmaceuticals, Inc., Merck KGaA, Pfizer Inc., RLC Labs, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Viatris.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Thyroid Eye Disease Treatments Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Thyroid Eye Disease Treatments Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Thyroid Eye Disease Treatments Market?
4. What is the competitive strategic window for opportunities in the Global Thyroid Eye Disease Treatments Market?
5. What are the technology trends and regulatory frameworks in the Global Thyroid Eye Disease Treatments Market?
6. What is the market share of the leading vendors in the Global Thyroid Eye Disease Treatments Market?
7. What modes and strategic moves are considered suitable for entering the Global Thyroid Eye Disease Treatments Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High Prevalence of Autoimmune Diseases such as Grave’s Disease and Hashimoto’s Thyroiditis
5.1.1.2. Awareness Raising National Health Programs Coupled with Favorable Reimbursement Policies related to Thyroid Disease Treatment
5.1.1.3. Increasing Iodine Disorder and Thyroid Tumors Screening
5.1.2. Restraints
5.1.2.1. Limited Accessibility, Affordability, and Unmeasured Side Effects
5.1.3. Opportunities
5.1.3.1. Improving Healthcare Infrastructure, Increasing Number of Ophthalmologists
5.1.3.2. Growing Early Diagnosis Rate Coupled with Developing Novel Therapy for the Thyroid Eye
5.1.4. Challenges
5.1.4.1. Limitation Associated with the Availability of any Definitive Thyroid Eye Treatment
5.2. Cumulative Impact of COVID-19
6. Thyroid Eye Disease Treatments Market, by Drug
6.1. Introduction
6.2. Corticosteroid
6.3. Monoclonal Antibody
6.4. Vitamin
7. Thyroid Eye Disease Treatments Market, by Route of Administration
7.1. Introduction
7.2. Oral
7.3. Topical
8. Thyroid Eye Disease Treatments Market, by Treatment
8.1. Introduction
8.2. Medication
8.3. Radioactive Iodine Therapy
8.4. Surgery
9. Thyroid Eye Disease Treatments Market, by Diagnosis
9.1. Introduction
9.2. Blood Test
9.3. Imaging Test
9.4. Physical Exam
9.5. Radioactive Iodine Uptake Test
9.6. Orbital Ultrasound
10. Thyroid Eye Disease Treatments Market, by Distribution
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Americas Thyroid Eye Disease Treatments Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Thyroid Eye Disease Treatments Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Thyroid Eye Disease Treatments Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. AbbVie, Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Akron Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. AMRI Global
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Bausch & Lomb Incorporated
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Bayer AG
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Eyevance Pharmaceuticals LLC
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Fujifilm Holdings Corporation
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. GlaxoSmithKline PLC
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Horizon Therapeutics PLC
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Immunovant, Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Kala Pharmaceuticals, Inc.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Merck KGaA
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Pfizer Inc.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. RLC Labs
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Sanofi S.A.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Teva Pharmaceutical Industries Ltd.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Viatris
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing